Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, anti-TB, cephalosporins, and nonsteroidal anti-inflammatory drug therapies.
Ver gráficos interactivos y estados completos →
| Cuenta de resultados | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Ingresos totales | ₹274.9B | ₹221.9B | ₹196.6B | ₹162.7B |
| Beneficio bruto | ₹193.8B | ₹147.4B | ₹125.1B | ₹90.1B |
| Ingresos operativos (EBIT) | ₹68.2B | ₹43.5B | ₹28.0B | ₹8.9B |
| Ingresos netos | ₹53.3B | ₹32.8B | ₹19.1B | ₹4.3B |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de LUPIN. /companies/us/LUPIN
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms